Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: The state of the art

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 2, 2006, Pages 113-120

  Wróblewska, Marta ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Acinetobacter; Antimicrobial therapy; Pseudomonas; Vaccines

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; DOXYCYCLINE; IMIPENEM; MEROPENEM; NALIDIXIC ACID; POLYMYXIN; PSEUDOMONAS VACCINE; RIFAMPICIN; SULBACTAM; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VIRULENCE FACTOR;

ACINETOBACTER; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; DNA MODIFICATION; DRUG POTENTIATION; EPIDEMIC; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW;

ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VACCINES;

EID: 33747457410     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0012-4     Document Type: Review

References (85)

1. Alisky J., Iczkowski K., Rapoport A. and Troitsky N. (1998): Bacteriophages show promise as antimicrobial agents. J. Infect., 36, 5-15.
2. Appleman M. D., Belzberg H., Citron D. M., Heseltine P. N., Yellin A. E., Murray J. and Berne T. V. (2000): In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob. Agents Chemother., 44, 1035-1040.
3. Aubert G., Guichard D. and Vedel G. (1996): In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. J. Antimicrob. Chemother., 37, 155-160.
4. Blot S., Vandewoude K., Hoste E. and Colardyn F. (2003): Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J. Hosp. Infect., 53, 18-24.
5. Bouza E., Garcia-Garrote F., Cercenado E., Marin M and Diaz M. S. (1999): Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. Antimicrob. Agents Chemother., 43, 981-982.
6. Bukholm G., Tannaes T., Kjelsberg A. B. and Smith-Erichsen N. (2002): An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect. Control Hosp. Epidemiol., 23, 441-446.
7. Buynak J. D. (2004): The discovery and development of modified penicillin- and caphalosporin-derived β-lactamase inhibitors. Curr. Med. Chem., 11, 1951-1964.
8. Cachia P. J. and Hodges R. S. (2003): Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa. Biopolymers, 71: 141-168.
9. Carfartan G., Gerardin P., Turck D. and Husson M.-O. (2004): Effect of subinhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to bronchial mucins collected from cystic fibrosis patients. J. Antimicrob. Chemother., 53, 686-688.
10. Centers for Disease Control and Prevention (CDC) (2004): Acinetobacter baumannii infections among patients at military medical facilities treating injured U. S. service members, 2002-2004. WR Morb Mortal Wkly Rep., 53, 1063-1066.
11. Clements J. M., Ayscough A. P., Keavey K. and East S. P. (2002): Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials. Curr. Med. Chem. Anti-Infect. Agents, 1, 239-249.
12. Coban A. Y., Ekinci B. and Durupinar B. (2004): A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy, 50, 22-26.
13. Corbella X., Montero A., Pujol M., Dominguez M. A., Ayats J., Argerich M. J., Argerich M. J., Garrigosa F., Ariza J. and Gudiol F. (2000): Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol., 38, 4086-4095.
14. Craig W. A. (1997): The pharmacology of meropenem, a new carbapenem antibiotic. Clin. Infect. Dis., 24 (suppl. 2), S266-S275.
15. Cryz S.J., Lang A.B., Rudeberg A., Wedgwood J., Que J.U., Furer E. and Schaad U.B. (1997): Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst. Mitt., 98, 345-349.
16. Doring G. and Dorner F. (1997): A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst. Mitt., 98, 338-344.
17. Dubois V., Arpin C., Melon M., Melon B., Andre C., Frigo C. and Quentin C. (2001): Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J. Clin. Microbiol., 39, 2072-2078.
18. Ermertcan S., Hosgor M., Tunger O. and Cosar G. (2001): Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections. Scand. J. Infect. Dis., 33, 818-821.
19. Evans M. E., Feola D. J. and Rapp R. P. (1999): Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother., 33, 960-967.
20. Falagas M. E., Bliziotis I. A., Kasiakou S. K., Samonis G., Athanassopoulou P. and Michalopoulos A. (2005): Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis., 5, 24-30.
21. Fierobe L., Lucet J.-C., Decre D., Muller-Serieys C., Deleuze A., Joly-Guillou M.-L., Mantz J. and Desmonts J. M. (2001): An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect. Control Hosp. Epidemiol., 22, 35-40.
22. Friedland I., Stinson L., Ikaiddi M., Harm S. and Woods G. L. (2003): Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000. Diagn. Microbiol. Infect. Dis., 45, 245-250.
23. Giamarellos-Bourboulis E. J., Grecka P. and Giamarellou H. (1996): In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. J. Antimicrob. Chemother., 38, 287-291.
24. Giamarellos-Bourboulis E. J., Sambatakou H., Galani I. and Giamarellou H. (2003): In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J. Chemother., 15, 235-238.
25. Giamarellou H. (2002): Prescribing guidelines for severe Pseudomonas infections. J. Antimicrob. Chemother., 49, 229-233.
26. Gilleland H. E., Gilleland L. B., Staczek J., Harty R. N., Garcia-Sastre A., Palese P., Brennan F. R., Hamilton W. D., Bendahmane M. and Beachy R. N. (2000): Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection. FEMS Immunol. Med. Microbiol., 27, 291-297.
27. Gillis R. J. and Iglewski B. H. (2004): Azithromycin retards Pseudomonas aeruginosa biofilm formation. J. Clin. Microbiol., 42, 5842-5845.
28. Go E. S., Urban C., Burns J., Kreiswirth B., Eisner W., Mariano N., Mosinka-Snipas K. and Rahal J. J. (1994): Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet, 344, 1329-1332.
29. Gunderson B. W., Ibrahim K. H., Hovde L. B., Fromm T. L., Reed M. D. and Rotschafer J. C. (2003): Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents. Chemother., 47, 905-909.
30. Hagens S., Habel A., von Ahsen U., von Gabain A. and Bläsi U. (2004): Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother., 48, 3817-3822.
31. Hamer D. H. (2000): Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am. J. Respir. Crit. Care Med., 162, 328-330.
32. Hassett D. J., Cuppoletti J., Trapnell B., Lymar S. V., Rowe J. J., Yoon S. S., Hilliard G. M., Parvatiyar K., Kamani M. C., Wozniak D. J., Hwang S. H., McDermott T. R. and Ochsner U. A. (2002): Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv. Drug Deliv. Rev., 54, 1425-1443.
33. Hentzer M., Wu H., Andersen J. B., Riedel K., Rasmussen T. B., Bagge N., Kumar N., Schembri M. A., Song Z., Kristoffersen P., Manefield M., Costerton J. W., Molin S., Eberl L., Steinberg P., Kjelleberg S., Hoiby N. and Givskov M. (2003): Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J., 22, 3803-3815.
34. Henwood C. J., Gatward T., Warner M., James D., Stockdale M. W., Spence R. P., Towner K. J., Livermore D. M. and Woodford N. (2002): Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother., 49, 479-487.
35. Hertle R., Mrsny R. and Fitzgerald D. J. (2001): Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein. Infect. Immun., 69, 6962-6969.
36. Higgins P. G., Wisplinghoff H., Stefanik D. and Seifert H. (2004): In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob. Agents Chemother., 48, 1586-1592.
37. Hoang T. T. and Schweizer H. P. (1999): Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis. J. Bacteriol., 181, 5489-5497.
38. Hsueh P. R., Liu Y. C., Yang D., Yan J. J., Wu T. L., Huang W. K., Wu J. J., Ko W. C., Leu H. S., Yu C. R. and Luh K. T. (2001): Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb. Drug Resit., 7, 373-382.
39. Hsueh P. R., Teng L. J., Chen C. Y., Chen W. H., Yu C. J., Ho S. W. and Luh K. T. (2002): Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg. Infect. Dis., 8, 827-832.
40. Husni R. N., Goldstein L. S. Arroliga A. C., Hall G. S., Fatica C., Stoller J. K. and Gordon S. M. (1999): Risk factors for an outbreak of multi-drug resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest, 115, 1378-1382.
41. Jain R. and Danziger L. H. (2004): Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother., 38, 1449-1459.
42. Jamieson C. E., Lambert P. A. and Simpson I. N. (2003): In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother., 47, 2615-2618.
43. Johnson K. W., Lofland D. and Moser H. E. (2005): PDF inhibitors: an emerging class of antibacterial drugs. Curr. Drug Targets Infect. Disord., 5, 39-52.
44. Karlowsky J. A., Draghi D. C., Jones M. E., Thornsberry C., Friedland I. R. and Sahm D. F. (2003): Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother., 47, 1681-1688.
45. Landman D., Bratu S., Alam M. and Quale J. (2005): Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob. Chemother., 55, 954-957.
46. Landman D., Quale J. M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., Flores C. and Brooks S. (2002): Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med., 162, 1515-1520.
47. Lang A. B., Rudeberg A., Schoni M. H., Que J. U., Furer E. and Schaad U. B. (2004): Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J., 23, 504-510.
48. Lee S.-O., Kim N. J., Choi S.-H., Hyong Kim T., Chung J.-W., Woo J.-H., Ryu J. and Kim Y. S. (2004): Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case control study. Antimicrob. Agents Chemother., 48, 224-228.
49. Levin A. S. (2002): Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin. Microbiol. Infect., 8, 144-153.
50. Levin A. S. (2003): Treatment of Acinetobacter spp. infections. Exp. Opin. Pharmacother., 4, 1289-1296.
51. Linden P. K., Kusne S., Coley K., Fontes P., Kramer D. J. and Paterson D. (2003): Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis., 37, 154-160.
52. Livermore D. M., Mushtaq S. and Warner M. (2005): Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J. Antimicrob. Chemother., 55, 306-311.
53. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.-D., Gilleland H. E. Jr., Staczek J., Domdey H. and von Specht B. U. (1999): Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun., 67, 1461-1470.
54. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutsoukou A., Alamanos I. and Gregorakos L. (2003): Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care, 7, R78-R83.
55. McQuillen D. P., Duncan R. A. and Craven D. E. (2005): Ventilator-associated pneumonia: emerging principles of management. Infect. Med., 22, 104-118.
56. Michalopoulos A., Kasiakou S. K., Rosmarakis E. S. and Falagas M. E. (2005): Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand. J. Infect. Dis., 37, 142-145.
57. Milatovic D., Schmitz F.-J., Verhoef J. and Fluit A. C. (2003): Activities of the glycylcycline tigecycline (GAR-936) against, 1924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother., 47, 400-404.
58. Miler J. M., Spilsbury J. F., Jones R. J., Roe E. A. and Lowbury E. J. (1977): A new polyvalent Pseudomonas vaccine. J. Med. Microbiol., 10, 19-27.
59. Molinari G., Guzman C. A., Pesce A. and Schito G. C. (1993): Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolides. J. Antimicrob. Chemother., 31, 681-688.
60. Montero A., Ariza J., Corbella X., Domenech A., Cabellos C., Ayats J., Tubau F., Ardanuy C. and Gudiol F. (2002): Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob. Agents Chemother., 46, 1946-1952.
61. Navon-Venezia S., Ben-Ami R. and Carmeli Y. (2005): Update on Pseudomonas seruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr. Opin. Infect. Dis., 18, 306-313.
62. Obana Y., Nishino T. and Tanino T. (1982): Studies on Acinetobacter calcoaceticus. Protective effects of antiserum and vaccine to infection. Kansenshogaku Zasshi, 56, 762-768.
63. Oie S., Uematsu T., Sawa A., Mizuno H., Tomita M., Ishida S., Okano Y. and Kamiya A. (2003): In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother., 52, 911-914.
64. Payne D. J., Miller W. H., Berry V., Brosky J., Burgess W. J., Chen E., DeWolf W. E. Jr., Fosberry A. P., Greenwood R., Head M. S., Heerding D. A., Janson C. A., Jaworski D. D., Keller P. M., Manley P. J., Moore T. D., Newlander K. A., Pearson S., Polizzi B. J., Qiu X., Rittenhouse S. F., Slater-Radosti C., Salyers K. L., Seefeld M. A., Smyth M. G., Takata D. T., Uzinskas I. N., Vaidya K., Wallis N. G., Winram S. B., Yuan C. C. and Huffman W. F. (2002): Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother., 46, 3118-3124.
65. Pier G. B., DesJardin D., Grout M., Garner C., Bennett S. E., Pekoe G., Fuller S. A., Thornton M. O., Harkonen W. S. and Miller H. C. (1994): Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun., 62, 3972-3979.
66. Polk R. E., Johnson C. K., McClish D., Wenzel R. P. and Edmond M. B. (2004): Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin. Infect. Dis., 39, 497-503.
67. Ramsey D. M. and Wozniak D. J. (2005): Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol. Microbiol., 56, 309-322.
68. Rodriguez-Hernandez M. J., Pachon J., Pichardo C., Cuberos L., Ibanez-Martinez J., Garcia-Curiel A., Caballero F. J., Moreno I. and Jimenez-Mejias M. E. (2000): Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother., 45, 493-501.
69. Ruiz J., Nunez M. L., Perez J., Simarro E., Martinez-Campos L. and Gomez J. (1999): Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur. J. Clin. Microbiol. Infect. Dis., 18, 292-295.
70. Saiman L., Chen Y., Gabriel P. S. and Knirsch C. (2002): Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother., 46, 1105-1107.
71. Smith R. S. and Iglewski B. H. (2003): Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J. Clin. Invest., 112, 1460-1465.
72. Soothill J. S. (1992): Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol., 37, 258-261.
73. Soothill J. S. (1994): Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns, 20, 209-211.
74. Stanislavsky E. S. and Lam J. S. (1997): Pseudomonas aeruginosa antigens as potential vaccines. FEMS Microbiol. Rev., 21, 243-277.
75. Sulakvelidze A., Alavidze Z. and Morris J. G. (2001): Bacteriophage therapy. Antimicrob. Agents Chemother., 45, 649-659.
76. Tablan O. C., Anderson L. J., Besser R., Bridges C., Hajjeh R. and Healthcare Infection Control Practices Advisory Committee (2004): Guidelines for preventing health-care-associated pneumonia, 2003 recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR, 53, 1-36.
77. Theilacker C., Coleman F. T., Mueschenborn S., Llosa N., Grout M. and Pier G. B. (2003): Construction and characterization of Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect. Immun., 71, 3875-3884.
78. Tsuji M., Takema M., Miwa H., Shimada J. and Kuwahara S. (2003): In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob. Agents Chemother., 47, 2507-2512.
79. Van Looveren M., Goossens H. and the ARPAC Steering Group (2004): Antimicrobial resistance of Acinetobacter spp. in Europe. Clin. Microbiol. Infect., 10, 684-704.
80. Watanabe A., Takahashi H., Kikuchi T., Kobayashi T., Gomi K., Fujimura S., Yasui S., Murayama Y. and Nukiwa T. (2000): Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy, 46, 184-187.
81. Weiss W. J., Petersen P. J., Murphy T. M., Tardio L. A., Yang Y., Bradford P. A., Venkatesan A. M., Abe T., Isoda T., Mihira A., Ushirogochi H., Takasake T., Projan S., O'Connell J. and Mansour T. S. (2004): In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob. Agents Chemother., 48, 4589-4596.
82. Worgall S., Krause A., Rivara M., Hee K.-K., Vintayen E. V., Hackett N. R. Roelvink P. W., Bruder J. T., Wickham T. J., Kovesdi I. and Crystal R. G. (2005): Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest., 115, 1281-1289.
83. Wozniak D. J and Keyser R. (2004): Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest, 125, 62S-69S.
84. Wróblewska M. M., Dijkshoorn L., Marchel H., van den Barselaar M., Swoboda-Kopec E., van den Broek P. J. and Luczak M. (2004): Outbreak of nosocomial meningitis caused by Acinetobacter baumannii in neurosurgical patients. J. Hosp. Infect., 57, 300-307.
85. Wu H., Song Z., Hentzer M., Andersen J. B., Molin S., Givskov M. and Hoiby N. (2004): Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother., 53, 1054-1061.